Literature DB >> 31722988

Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.

Warren Anderson1,2, Jerill Thorpe3, S Alice Long3, David J Rawlings4,5,6.   

Abstract

Risk of autoimmunity is associated with multiple genetic variants. Genome-wide association studies have linked single-nucleotide polymorphisms in the phosphatases PTPN22 (rs2476601) and PTPN2 (rs1893217) to increased risk for multiple autoimmune diseases. Previous mouse studies of loss of function or risk variants in these genes revealed hyperactive T cell responses, whereas studies of human lymphocytes revealed contrasting phenotypes. To better understand this dichotomy, we established a robust gene editing platform to rapidly address the consequences of loss of function of candidate genes in primary human CD4+ T cells. Using CRISPR/Cas9, we obtained efficient gene disruption (>80%) of target genes encoding proteins involved in Ag and cytokine receptor signaling pathways including PTPN22 and PTPN2 Loss-of-function data in all genes studied correlated with previous data from mouse models. Further analyses of PTPN2 gene-disrupted T cells demonstrated dynamic effects, by which hyperactive IL-2R signaling promoted compensatory transcriptional events, eventually resulting in T cells that were hyporesponsive to IL-2. These results imply that altered phosphatase activity promotes evolving phenotypes based on Ag experience and/or other programming signals. This approach enables the discovery of molecular mechanisms modulating risk of autoimmunity that have been difficult to parse in traditional mouse models or cross-sectional human studies.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31722988      PMCID: PMC6904544          DOI: 10.4049/jimmunol.1900848

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3.

Authors:  Paul D Simoncic; Ailsa Lee-Loy; Dwayne L Barber; Michel L Tremblay; C Jane McGlade
Journal:  Curr Biol       Date:  2002-03-19       Impact factor: 10.834

Review 2.  PTPN22: the archetypal non-HLA autoimmunity gene.

Authors:  Stephanie M Stanford; Nunzio Bottini
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 3.  Autoimmune diseases - connecting risk alleles with molecular traits of the immune system.

Authors:  Maria Gutierrez-Arcelus; Stephen S Rich; Soumya Raychaudhuri
Journal:  Nat Rev Genet       Date:  2016-02-15       Impact factor: 53.242

4.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.

Authors:  Blythe D Sather; Guillermo S Romano Ibarra; Karen Sommer; Gabrielle Curinga; Malika Hale; Iram F Khan; Swati Singh; Yumei Song; Kamila Gwiazda; Jaya Sahni; Jordan Jarjour; Alexander Astrakhan; Thor A Wagner; Andrew M Scharenberg; David J Rawlings
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

5.  Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.

Authors:  Julie Zikherman; Arthur Weiss
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

6.  Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function.

Authors:  Brendan B L Pillemer; Hui Xu; Timothy B Oriss; Zengbiao Qi; Anuradha Ray
Journal:  Eur J Immunol       Date:  2007-08       Impact factor: 5.532

7.  p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.

Authors:  Robert J Ihry; Kathleen A Worringer; Max R Salick; Elizabeth Frias; Daniel Ho; Kraig Theriault; Sravya Kommineni; Julie Chen; Marie Sondey; Chaoyang Ye; Ranjit Randhawa; Tripti Kulkarni; Zinger Yang; Gregory McAllister; Carsten Russ; John Reece-Hoyes; William Forrester; Gregory R Hoffman; Ricardo Dolmetsch; Ajamete Kaykas
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440

8.  Sequence-specific activation of the DNA sensor cGAS by Y-form DNA structures as found in primary HIV-1 cDNA.

Authors:  Anna-Maria Herzner; Cristina Amparo Hagmann; Marion Goldeck; Steven Wolter; Kirsten Kübler; Sabine Wittmann; Thomas Gramberg; Liudmila Andreeva; Karl-Peter Hopfner; Christina Mertens; Thomas Zillinger; Tengchuan Jin; Tsan Sam Xiao; Eva Bartok; Christoph Coch; Damian Ackermann; Veit Hornung; Janos Ludwig; Winfried Barchet; Gunther Hartmann; Martin Schlee
Journal:  Nat Immunol       Date:  2015-09-07       Impact factor: 25.606

9.  Genetic regulatory effects modified by immune activation contribute to autoimmune disease associations.

Authors:  Sarah Kim-Hellmuth; Matthias Bechheim; Benno Pütz; Pejman Mohammadi; Yohann Nédélec; Nicholas Giangreco; Jessica Becker; Vera Kaiser; Nadine Fricker; Esther Beier; Peter Boor; Stephane E Castel; Markus M Nöthen; Luis B Barreiro; Joseph K Pickrell; Bertram Müller-Myhsok; Tuuli Lappalainen; Johannes Schumacher; Veit Hornung
Journal:  Nat Commun       Date:  2017-08-16       Impact factor: 14.919

10.  Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.

Authors:  Akiko Seki; Sascha Rutz
Journal:  J Exp Med       Date:  2018-02-07       Impact factor: 14.307

View more
  12 in total

Review 1.  Genome editing to define the function of risk loci and variants in rheumatic disease.

Authors:  Yuriy Baglaenko; Dana Macfarlane; Alexander Marson; Peter A Nigrovic; Soumya Raychaudhuri
Journal:  Nat Rev Rheumatol       Date:  2021-06-29       Impact factor: 20.543

2.  CRISPR/Cas9-Mediated Insertion of HIV Long Terminal Repeat within BACH2 Promotes Expansion of T Regulatory-like Cells.

Authors:  Michelle L Christian; Michael J Dapp; Samuel C Scharffenberger; Hank Jones; Chaozhong Song; Lisa M Frenkel; Anthony Krumm; James I Mullins; David J Rawlings
Journal:  J Immunol       Date:  2022-03-09       Impact factor: 5.422

Review 3.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

Review 4.  Genetic engineering of T cells for immunotherapy.

Authors:  Gavin I Ellis; Neil C Sheppard; James L Riley
Journal:  Nat Rev Genet       Date:  2021-02-18       Impact factor: 59.581

Review 5.  Using CRISPR to enhance T cell effector function for therapeutic applications.

Authors:  Julian J Freen-van Heeren
Journal:  Cytokine X       Date:  2020-12-21

Review 6.  Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.

Authors:  Lucas H Armitage; Mark A Wallet; Clayton E Mathews
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

7.  Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation.

Authors:  Daniel J Perry; Leeana D Peters; Priya Saikumar Lakshmi; Lin Zhang; Zhao Han; Clive H Wasserfall; Clayton E Mathews; Mark A Atkinson; Todd M Brusko
Journal:  J Immunol       Date:  2021-07-23       Impact factor: 5.426

8.  UBASH3A deficiency accelerates type 1 diabetes development and enhances salivary gland inflammation in NOD mice.

Authors:  Yi-Guang Chen; Ashley E Ciecko; Shamim Khaja; Michael Grzybowski; Aron M Geurts; Scott M Lieberman
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

9.  T cells selectively filter oscillatory signals on the minutes timescale.

Authors:  Geoff P O'Donoghue; Lukasz J Bugaj; Warren Anderson; Kyle G Daniels; David J Rawlings; Wendell A Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

10.  Systems-level conservation of the proximal TCR signaling network of mice and humans.

Authors:  Philippe Nicolas; Jocelyn Ollier; Daiki Mori; Guillaume Voisinne; Javier Celis-Gutierrez; Béatrice Clémenceau; Romain Roncagalli; Claude Gregoire; Jeanne Perroteau; Régine Vivien; Mylène Camus; Odile Burlet-Schiltz; Anne Gonzalez de Peredo; Henri Vié; Bernard Malissen
Journal:  J Exp Med       Date:  2022-01-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.